NUCALA Subcutaneous Injection Special Drug Use Investigation (EGPA, Long-term)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Mepolizumab (Primary)
- Indications Churg-Strauss syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Aug 2018 Status changed from not yet recruiting to recruiting.
- 02 Jul 2018 Planned initiation date changed from 1 Jul 2018 to 25 Jun 2018.